In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed:

1. MIPS PV scoring system

https://pubmed.ncbi.nlm.nih.gov/31945802/

2. REVEAL study

https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell

3. MAJIC PV study

https://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

4. Cyto-PV Study

https://www.nejm.org/doi/full/10.1056/NEJMoa1208500

5. PROUD-PV and CONTINUATION-PV trials

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30236-4/abstract

6. RESPONSE clinical trial

https://www.nejm.org/doi/full/10.1056/NEJMoa1409002

7. Rusferitide in PV

https://www.nejm.org/doi/10.1056/NEJMoa2308809?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:

1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL

https://library.ehaweb.org/eha/2024/eha2024-congress/4136516

2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):

https://library.ehaweb.org/eha/2024/eha2024-congress/422343

3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740

4. ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515

5. HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext

6. Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268

7. Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267

In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed:

1. Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL0

2. EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/38768337/

3. Predictors of un-sustained MRD-negativity in multiple myeloma:

a) Secondary analysis of FORTE trial: https://pubmed.ncbi.nlm.nih.gov/38048557/

b) Secondary analysis of GEM2012MENOS65 and GEM2014MAIN trials: https://pubmed.ncbi.nlm.nih.gov/38048552/

4. Kinetics of MRD resurgence and subsequent relapse in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34807986/

5. MRD2STOP trial (MRD-guided maintenance discontinuation): https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.106

6. MRD-guided maintenance discontinuation in myeloma (Secondary analysis of GEM2012MENOS65 trial): https://pubmed.ncbi.nlm.nih.gov/37506339/